Linnea SA, a global active pharmaceutical ingredients manufacturer, is pleased to announce the start of a strategic partnership with the Universidade Estadual de Campinas (UniCamp), a public research university in the state of São Paulo, Brazil.
The cannabinoid market in Latin America has been growing over the last years as a result of patients' demand for safe, reliable and effective therapy.
The current cannabinoid delivery forms are often not aligned with the standards of quality typical of the pharmaceutical world and necessary to ensure the safety and the efficacy for patients.
As the demand for cannabinoid therapies rises, health authorities are gradually creating rules to protect consumers and help healthcare personnel to identify the best cannabinoid treatments.
To help accelerate this process, Linnea SA and Unicamp are now working together on the development of cannabinoid-based products in alignment with current and future medical needs. Linnea SA and Unicamp believe promoting science through high-quality products can help people to receive better treatments.
Linnea SA currently sells their botanical nature derived APIs, including cannabinoids, to over 300 business partners in over 70 different countries worldwide.
It is proud to promote the best practices and show commitment to ongoing scientific research and development through global strategic partnerships.
